Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5621-5630 Newer>

Pharmaceutical Executive May 1, 2009 Maryann Kuzel	Weathering the Storm Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market.
Pharmaceutical Executive May 1, 2009 Lee Slovitt	A Day Late and a Dollar Short Pharma marketers face a crisis in digital media. But there's a way to turn it around.
Pharmaceutical Executive May 1, 2009 Jill Wechsler	Compared to What? Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.
The Motley Fool May 13, 2009 Brian Orelli	Icahn's an Energizer Pit Bull He keeps going and doesn't let go.
The Motley Fool May 12, 2009 Brian Orelli	Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool May 11, 2009 Brian Orelli	Brilliant, Now Let's See the Data AstraZeneca's investors today should be cautiously optimistic about Brilinta. It could be a blockbuster for the company, but it may need some brilliant marketing to compete.
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?
The Motley Fool May 8, 2009 Brian Orelli	Growth in All the Wrong Places The potential of Onyx's tumor drug Nexavar will always be a major component in the company's value, but investors should watch the growth in current indications -- and where it's coming from -- in case the additional indications don't pan out.
<Older 5621-5630 Newer> Return to current articles.